PTO/SB06a (05-07)

Approved for use through 09/30/2007 OMB 0851-0031

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contrars a valid OMB control number.

16CT01218

Attorney Docket Number

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	atent Number Kind Code1 Issue Date Name of Patentee or Applicar of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1										
If you wis	h to a	i dd additional U.S. Patei	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant R		Releva		Lines where ges or Relev	
	1										
If you wisi	h to a	dd additional U.S. Publi		,		n information p		d button	Add		
				FUREI	3N PA	ENI DOCUM	I	1		umns,Lines	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	where Rel	evant or Relevant	T=
	1	2002-24380	JP			2002-01-25	NEC Saltama LTD				
	2	EP1229472	EP		A1	2002-07-08	Kabushiki Kaisha 7	oshiba			С
	3	WO0224062	wo		A1	2002-03-28	Telectroscan, Inc.				

# | Application Number | 10627216 | Filing Date | 2003 07-25 | Filing Date |

If you wis	n to a	dd add	itional Foreign Patent Document citation information please click the Add bu		
			NON-PATENT LITERATURE DOCUMENTS	Remove	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the iter (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and offic country where published.					
	1	Pater	tt Abstract and English Language Translation of JP2002-24380 (18 pgs.)		
If you wis	h to a	dd add	itional non-patent literature document citation information please click the Ar	dd button Add	
			EXAMINER SIGNATURE		
Examiner	Signa	ture	Date Considered	i	

1 See Kind Code of USPTO Platent Documents at year, USPTO\_GOLY on MEPS 901.04. <sup>2</sup> Enter office that all seaso the document, by the lock-later code (WIPO Standard 51.3). <sup>2</sup> The Laplanese platent documents, the inclusion to the year of the setting of the Engerer must proceed the settle in Lamber 1 for planet document. <sup>2</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard 51.16 if possible. <sup>3</sup> Applicant is to place a check mark here if Enginh Imagingae translation a statistical.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 GFR 1.99)

Application Number		10627216
Filing Date		2003-07-25
First Named Inventor Akira		Hagiwara
Art Unit		2612
Examiner Name		
Attorney Docket Number		16CT01218

### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1	.98 to make t	the appropria	priate selection(s):
---------------	----------	-------	---------------	---------------	----------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement.

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

▼ None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

of the agreeter.							
Signature	/pwt/	Date (YYYY-MM-DD)	2007-06-07				
Name/Print	Patrick W Rasche	Registration Number	37 916				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2313-1450. DIN OTS CRID FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2313-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.